Drug-Related Lipid Metabolism Abnormalities: A Real-World Pharmacovigilance Exploratory Analysis Based on U.S. FDA Adverse Event Reporting System (FAERS)

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

This case report suggests that long-acting injectable risperidone may induce hirsutism in some patients, and clinicians should monitor for this potential side effect when prescribing this antipsychotic.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.